ArticleFrontiers in surgery2025
Case Report: A rare small bowel sarcoma.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal sarcomas are rare gastrointestinal tumors but their etiology is not clear. A middle-aged man was admitted to hospital on 11 April 2023 because of intermittent melena for 1 month. Gastroscopy and colonoscopy were inconclusive, however, melena persisted. Abdominal magnetic resonance imaging indicated a left mid-abdominal mass and lymphoma of the small bowel origin. Small bowel enteroscopy revealed infiltrating periannular ulcer lesions in the jejunum. He underwent an operation and a partial resection of the small intestine was performed. The pathological examination revealed mesenchymal, highly malignant, poorly differentiated sarcoma. The patient died 6 months after surgery. The patient had been diagnosed with hepatocellular cancer and received immune checkpoint inhibitors (PD-1, sintilimab) combined with bevacizumab for 14 cycles 19 months before being diagnosed with intestinal sarcoma, and achieved complete remission. While immunotherapy achieves good therapeutic effects, another problem that has to be paid attention to is immune-related adverse reactions, which involve multiple systems. Based on the above information, we believe that this small bowel sarcoma was a rare complication of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.